Dabrafenib + Trametinib
Treatment for Malignant Skin Melanoma
Typical Dosage: Dabrafenib 150mg orally twice daily + Trametinib 2mg orally once daily
Effectiveness
91%
Safety Score
38%
Clinical Trials
18
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe
Treatment Details
Dosage Range
Dabrafenib 150mg orally twice daily + Trametinib 2mg orally once daily
Time to Effect
1-2 months
Treatment Duration
1-2 years
Evidence Quality
HIGHConfidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$320,000
Monitoring:$12,000
Side Effect Mgmt:$10,000
Total Annual:$342,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$526,154
Cost per Remission
$2,280,000
Comparison vs Vemurafenib
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Dabrafenib + Trametinib Outcomes
for Malignant Skin Melanoma
Efficacy Outcomes
Overall Effectiveness
+91%
Response Rate
+65%
Remission Rate
+15%
Common Side Effects
Pyrexia (fever)
+60%
Fatigue
+40%
Nausea, Diarrhea, Vomiting
+30%
Chills
+25%
Rash
+25%
Peripheral edema
+25%
Active Clinical Trials
6 active trials recruiting for Dabrafenib + Trametinib in Malignant Skin Melanoma
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
NCT01972347ACTIVE NOT RECRUITINGPHASE2
35 participants
INTERVENTIONAL
Wollstonecraft, Australia
Started: Oct 1, 2014
Melanoma Metastasized to the Brain and Steroids
NCT03563729RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Herlev, Denmark +2 more
Started: Jun 6, 2018
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
NCT02910700ACTIVE NOT RECRUITINGPHASE2
52 participants
INTERVENTIONAL
Houston, United States
Started: Dec 9, 2016
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
NCT01989585ACTIVE NOT RECRUITINGPHASE1, PHASE2
75 participants
INTERVENTIONAL
Phoenix, United States +48 more
Started: Mar 24, 2014
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT04949113ACTIVE NOT RECRUITINGPHASE3
423 participants
INTERVENTIONAL
Los Angeles, United States +23 more
Started: Jul 8, 2021
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060ACTIVE NOT RECRUITINGPHASE2
6.45K participants
INTERVENTIONAL
Birmingham, United States +1413 more
Started: Aug 17, 2015
Completed Clinical Trials
7 completed trials for Dabrafenib + Trametinib in Malignant Skin Melanoma
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
NCT04547946COMPLETED
3 participants
OBSERVATIONAL
Coimbra, Portugal +1 more
Started: Oct 15, 2021
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
NCT03551626COMPLETEDPHASE3
552 participants
INTERVENTIONAL
Rosario, Argentina +99 more
Started: Aug 29, 2018
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
NCT02296996COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Brussels, Belgium
Started: Oct 1, 2014
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
NCT02439411COMPLETED
135 participants
OBSERVATIONAL
Almería, Spain +28 more
Started: Mar 3, 2015
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
NCT02083354COMPLETEDPHASE2
77 participants
INTERVENTIONAL
Guangzhou, China +12 more
Started: Mar 18, 2014
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
NCT07256184COMPLETED
232 participants
OBSERVATIONAL
Ankara, Turkey (Türkiye) +1 more
Started: Nov 15, 2022
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
NCT01902173COMPLETEDPHASE1, PHASE2
27 participants
INTERVENTIONAL
Los Angeles, United States +15 more
Started: Oct 8, 2013